Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Vincenzo Famiglietti
Observed names:
Famiglietti, Vincenzo,
V. Famiglietti
Institution:
University of Campania "Luigi Vanvitelli"
Observed institutions:
University of Campania "Luigi Vanvitelli",
Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli
ORCID:
0000-0002-5959-3838
Observed ORCID:
0000-0002-5959-3838
OpenAlex ID:
A5037047992
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial
2021
·
Erika Martinelli
, Giulia Martini
, et al.
·
JAMA Oncology
·
199
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
2022
·
Giulia Martini
, Davide Ciardiello
, et al.
·
International Journal of Cancer
·
79
PDF
Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
2023
·
Stefania Napolitano
, Vincenzo De Falco
, et al.
·
JAMA Oncology
·
71
PDF
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial
2024
·
Davide Ciardiello
, Erika Martinelli
, et al.
·
JAMA Network Open
·
68
PDF
Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience
2019
·
Pietro Paolo Vitiello
, Vincenzo De Falco
, et al.
·
Cancers
·
61
PDF
Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer
2020
·
Morena Fasano
, Carminia Maria Della Corte
, et al.
·
ESMO Open
·
50
Panitumumab plus trifluridine/tipiracil as anti‐ EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial
2023
·
Stefania Napolitano
, Davide Ciardiello
, et al.
·
International Journal of Cancer
·
41
PDF
HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study
2022
·
Francesca Carlino
, Anna Diana
, et al.
·
Cancers
·
39
PDF
Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
2021
·
Davide Ciardiello
, Giulia Martini
, et al.
·
Cancers
·
38
PDF
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival
2022
·
Davide Ciardiello
, Vincenzo Famiglietti
, et al.
·
Clinical Colorectal Cancer
·
34
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
2022
·
Vincenza Caputo
, Vincenzo De Falco
, et al.
·
Therapeutic Advances in Medical Oncology
·
31
PDF
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial
2022
·
Carminia Maria Della Corte
, Morena Fasano
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
26
PDF
397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study
2020
·
E. Martinelli
, G. Martini
, et al.
·
Annals of Oncology
·
25
Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’
2020
·
Vincenzo De Falco
, Luca Poliero
, et al.
·
ESMO Open
·
25
PDF
Cutaneous Metastasis from Colorectal Cancer: Making Light on an Unusual and Misdiagnosed Event
2021
·
Paola Parente
, Davide Ciardiello
, et al.
·
Life
·
23
PDF
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data
2021
·
Pasquale Vitale
, Nicoletta Zanaletti
, et al.
·
Clinical Colorectal Cancer
·
23
PDF
Real‐world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions
2023
·
Vincenzo De Falco
, Gabriella Suarato
, et al.
·
International Journal of Cancer
·
22
PDF
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAF V600E-Mutant Colorectal Cancer
2023
·
Stefania Napolitano
, Melanie Woods
, et al.
·
Clinical Cancer Research
·
19
PDF
Systemic-Inflammation-Based Score can Predict Prognosis in Metastatic Gastric Cancer Patients Before First-Line Chemotherapy
2018
·
Angelica Petrillo
, Maria Maddalena Laterza
, et al.
·
Future Oncology
·
19
Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
2022
·
Anna Diana
, Francesca Carlino
, et al.
·
Frontiers in Oncology
·
16
Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA : Individual patient data pooled analysis of CRICKET and CAVE trials
2023
·
G. Martini
, D. Ciardiello
, et al.
·
Cancer Medicine
·
15
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
2022
·
D. Ciardiello
, C. Chiarazzo
, et al.
·
ESMO Open
·
15
PDF
Temozolomide based treatment in glioblastoma: 6 vs. 12 months
2024
·
Morena Fasano
, Mario Pirozzi
, et al.
·
Oncology Letters
·
13
PDF
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials
2023
·
Davide Ciardiello
, Stefania Napolitano
, et al.
·
Cancers
·
13
PDF
Clinical activity of regorafenib in elderly patients with recurrent glioblastoma
2023
·
Morena Fasano
, Mario Pirozzi
, et al.
·
Molecular and Clinical Oncology
·
12
PDF
Show more works
View as search
Works count:
77
Citation count:
1,077
H-index:
19
I10-index:
29
Year
Topic
Type